

Catia Cilloniz

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4620254/catia-cilloniz-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

408
papers

15,932
citations

61
h-index

116
g-index

487
ext. papers

20,645
ext. citations

7.5
avg, IF

6.64
L-index

#	Paper	IF	Citations
408	Perspectives of patients, family members, health professionals and the public on the impact of COVID-19 on mental health.. <i>Journal of Mental Health</i> , 2022 , 1-10	2.7	
407	Impact of exposure time in awake prone positioning on clinical outcomes of patients with COVID-19-related acute respiratory failure treated with high-flow nasal oxygen: a multicenter cohort study.. <i>Critical Care</i> , 2022 , 26, 16	10.8	1
406	Severe Infections Due to Respiratory Viruses.. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2022 , 43, 60-74	3.9	0
405	Diagnóstico de la neumonía: una necesidad compartida. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2022 ,	0.9	
404	Ceftaroline Fosamil for the Empiric Treatment of Hospitalized Adults with cSSTI: An Economic Analysis from the Perspective of the Spanish National Health System.. <i>ClinicoEconomics and Outcomes Research</i> , 2022 , 14, 149-161	1.7	0
403	Ceftaroline in severe community-acquired pneumonia.. <i>Revista Espanola De Quimioterapia</i> , 2022 , 35 Suppl 1, 28-30	1.6	
402	Diagnostic concordance between BioFire® FilmArray® Pneumonia Panel and culture in patients with COVID-19 pneumonia admitted to intensive care units: the experience of the third wave in eight hospitals in Colombia.. <i>Critical Care</i> , 2022 , 26, 130	10.8	0
401	COVID-19 in patients aged 80 years and over during the peaks of the first three pandemic waves at a Spanish tertiary hospital. <i>Pneumon</i> , 2021 , 1-6		2
400	Impact on in-hospital mortality of ceftaroline versus standard of care in community-acquired pneumonia: a propensity-matched analysis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021 , 41, 271	5.3	
399	Differences between sexes concerning COVID-19-related pneumonia. <i>Panminerva Medica</i> , 2021 ,	2	2
398	Development and characterization of a new swine model of invasive pneumococcal pneumonia. <i>Lab Animal</i> , 2021 , 50, 327-335	0.4	
397	Empiric antibiotics for community-acquired pneumonia in adult patients: a systematic review and a network meta-analysis. <i>Thorax</i> , 2021 , 76, 1020-1031	7.3	0
396	Predictors of failure with high-flow nasal oxygen therapy in COVID-19 patients with acute respiratory failure: a multicenter observational study. <i>Journal of Intensive Care</i> , 2021 , 9, 23	7	11
395	The Evolution and Distribution of Pneumococcal Serotypes in Adults Hospitalized With Community-Acquired Pneumonia in Spain Using a Serotype-Specific Urinary Antigen Detection Test: The CAPA Study, 2011-2018. <i>Clinical Infectious Diseases</i> , 2021 , 73, 1075-1085	11.6	3
394	Lymphopenia Is Associated With Poor Outcomes of Patients With Community-Acquired Pneumonia and Sepsis. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab169	1	2
393	Bridging animal and clinical research during SARS-CoV-2 pandemic: A new-old challenge. <i>EBioMedicine</i> , 2021 , 66, 103291	8.8	9
392	Trends in mortality of hospitalised COVID-19 patients: A single centre observational cohort study from Spain. <i>Lancet Regional Health - Europe</i> , 2021 , 3, 100041		16

391	Pneumonia. <i>Nature Reviews Disease Primers</i> , 2021 , 7, 25	51.1	31
390	Predictive Performance of Risk Factors for Multidrug-Resistant Pathogens in Nosocomial Pneumonia. <i>Annals of the American Thoracic Society</i> , 2021 , 18, 807-814	4.7	0
389	Immunogenicity and crossreactivity of antibodies to the nucleocapsid protein of SARS-CoV-2: utility and limitations in seroprevalence and immunity studies. <i>Translational Research</i> , 2021 , 232, 60-74	11	29
388	Effects of Mechanical Insufflation-Exsufflation on Sputum Volume in Mechanically Ventilated Critically Ill Subjects. <i>Respiratory Care</i> , 2021 , 66, 1371-1379	2.1	1
387	Outcomes of Critically Ill Very Old Patients With Community-Acquired Pneumonia and Acute Respiratory Distress Syndrome. <i>Archivos De Bronconeumologia</i> , 2021 ,	0.7	
386	The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. <i>Lancet Respiratory Medicine</i> , 2021 , 9, 622-642	35.1	121
385	Pulse oximetry is an essential tool that saves lives: a call for standardisation. <i>European Respiratory Journal</i> , 2021 , 57,	13.6	
384	Tracheostomy Timing and Outcome in Severe COVID-19: The WeanTrach Multicenter Study. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	4
383	Impact of Cardiovascular Failure in Intensive Care Unit-Acquired Pneumonia: A Single-Center, Prospective Study. <i>Antibiotics</i> , 2021 , 10,	4.9	1
382	Community-acquired pneumonia severity assessment tools in patients hospitalized with COVID-19: a validation and clinical applicability study. <i>Clinical Microbiology and Infection</i> , 2021 , 27, 1037.e1-1037.e8	9.5	11
381	Age is a determinant of short-term mortality in patients hospitalized for an acute exacerbation of COPD. <i>Internal and Emergency Medicine</i> , 2021 , 16, 401-408	3.7	1
380	Biomarkers in the ICU: less is more? No. <i>Intensive Care Medicine</i> , 2021 , 47, 97-100	14.5	5
379	Strategies for implementation of a multidisciplinary approach to the treatment of nosocomial infections in critically ill patients. <i>Expert Review of Anti-Infective Therapy</i> , 2021 , 19, 759-767	5.5	0
378	Pulmonary Angiopathy in Severe COVID-19: Physiological Conclusions Derived from Ventilatory Ratio?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 203, 258-259	10.2	2
377	Methicillin-susceptible staphylococcus aureus in community-acquired pneumonia: Risk factors and outcomes. <i>Journal of Infection</i> , 2021 , 82, 76-83	18.9	2
376	Validation of a Prediction Score for Drug-Resistant Microorganisms in Community-acquired Pneumonia. <i>Annals of the American Thoracic Society</i> , 2021 , 18, 257-265	4.7	4
375	Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study. <i>Intensive Care Medicine</i> , 2021 , 47, 188-198	14.5	80
374	Core Outcome Measures for Trials in People With Coronavirus Disease 2019: Respiratory Failure, Multiorgan Failure, Shortness of Breath, and Recovery. <i>Critical Care Medicine</i> , 2021 , 49, 503-516	1.4	10

373	The Value of C-Reactive Protein-to-Lymphocyte Ratio in Predicting the Severity of SARS-CoV-2 Pneumonia. <i>Archivos De Bronconeumologia</i> , 2021 , 57, 79-82	0.7	4
372	Early oseltamivir treatment improves survival in critically ill patients with influenza pneumonia. <i>ERJ Open Research</i> , 2021 , 7,	3.5	4
371	Nosocomial Infection. <i>Critical Care Medicine</i> , 2021 , 49, 169-187	1.4	16
370	Nebulized antibiotics for ventilator-associated pneumonia: methodological framework for future multicenter randomized controlled trials. <i>Current Opinion in Infectious Diseases</i> , 2021 , 34, 156-168	5.4	2
369	High-flow nasal oxygen in patients with COVID-19-associated acute respiratory failure. <i>Critical Care</i> , 2021 , 25, 58	10.8	54
368	Corticosteroids for CAP, influenza and COVID-19: when, how and benefits or harm?. <i>European Respiratory Review</i> , 2021 , 30,	9.8	10
367	Omadacycline vs moxifloxacin in adults with community-acquired bacterial pneumonia. <i>International Journal of Infectious Diseases</i> , 2021 , 104, 501-509	10.5	1
366	Pulmonary Function and Radiologic Features in Survivors of Critical COVID-19: A 3-Month Prospective Cohort. <i>Chest</i> , 2021 , 160, 187-198	5.3	64
365	COVID-19 in young and middle-aged adults: predictors of poor outcome and clinical differences. <i>Infection</i> , 2021 , 1	5.8	3
364	Clinical and Microbiological Outcomes of Ceftazidime-Avibactam Treatment in Adults with Gram-Negative Bacteremia: A Subset Analysis from the Phase 3 Clinical Trial Program. <i>Infectious Diseases and Therapy</i> , 2021 , 10, 2399-2414	6.2	1
363	Aspiration pneumonia: A renewed perspective and practical approach. <i>Respiratory Medicine</i> , 2021 , 185, 106485	4.6	3
362	Criteria and definitions for the radiological and clinical diagnosis of bronchiectasis in adults for use in clinical trials: international consensus recommendations. <i>Lancet Respiratory Medicine</i> , 2021 ,	35.1	5
361	The evolution of the ventilatory ratio is a prognostic factor in mechanically ventilated COVID-19 ARDS patients. <i>Critical Care</i> , 2021 , 25, 331	10.8	4
360	Design and Rationale of a Prospective International Follow-Up Study on Intensive Care Survivors of COVID-19: The Long-Term Impact in Intensive Care Survivors of Coronavirus Disease-19-AFTERCOR. <i>Frontiers in Medicine</i> , 2021 , 8, 738086	4.9	1
359	Early Bacterial Identification Among Intubated Patients with COVID-19 or Influenza Pneumonia: A European Multicenter Comparative Cohort Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 ,	10.2	11
358	Circulating microRNA profiles predict the severity of COVID-19 in hospitalized patients. <i>Translational Research</i> , 2021 , 236, 147-159	11	29
357	Thrombocytosis during Stable State Predicts Mortality in Bronchiectasis. <i>Annals of the American Thoracic Society</i> , 2021 , 18, 1316-1325	4.7	2
356	New guidelines for severe community-acquired pneumonia. <i>Current Opinion in Pulmonary Medicine</i> , 2021 , 27, 210-215	3	1

355	Pulmonary infections complicating ARDS. <i>Intensive Care Medicine</i> , 2020 , 46, 2168-2183	14.5	19
354	Reply to "Dual Antibiotic Therapy for Outpatient Management of Community-Acquired Pneumonia?". <i>Archivos De Bronconeumologia</i> , 2020 , 56, 766-767	0.7	
353	Characteristics and Outcomes in Patients with Ventilator-Associated Pneumonia Who Do or Do Not Develop Acute Respiratory Distress Syndrome. An Observational Study. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	1
352	Difficult to treat microorganisms in patients aged over 80 years with community-acquired pneumonia: the prevalence of PES pathogens. <i>European Respiratory Journal</i> , 2020 , 56,	13.6	2
351	Community-acquired pneumonia in critically ill very old patients: a growing problem. <i>European Respiratory Review</i> , 2020 , 29,	9.8	21
350	Treatment of Community-Acquired Pneumonia in Immunocompromised Adults: A Consensus Statement Regarding Initial Strategies. <i>Chest</i> , 2020 , 158, 1896-1911	5.3	20
349	Promoting the use of social networks in pneumonia. <i>Pneumonia (Nathan Qld)</i> , 2020 , 12, 3	2.8	4
348	Ventilator-associated pneumonia: new principles guiding empiric antibiotic therapy. <i>Current Opinion in Infectious Diseases</i> , 2020 , 33, 182-188	5.4	1
347	The safety of antimicrobials for the treatment of community-acquired pneumonia. <i>Expert Opinion on Drug Safety</i> , 2020 , 19, 577-587	4.1	
346	Molecular characterization of methicillin-resistant Staphylococcus aureus clinical strains from the endotracheal tubes of patients with nosocomial pneumonia. <i>Antimicrobial Resistance and Infection Control</i> , 2020 , 9, 43	6.2	8
345	A Phase 2 Study of Pimodivir (JNJ-63623872) in Combination with Oseltamivir in Elderly and NonElderly Adults Hospitalized with Influenza A Infection: OPAL study. <i>Journal of Infectious Diseases</i> , 2020 ,	7	6
344	Q Fever (Coxiella Burnetii). <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020 , 41, 509-521	3.9	9
343	SARS-CoV-2-induced Acute Respiratory Distress Syndrome: Pulmonary Mechanics and Gas-Exchange Abnormalities. <i>Annals of the American Thoracic Society</i> , 2020 , 17, 1164-1168	4.7	15
342	Association between sepsis at ICU admission and mortality in patients with ICU-acquired pneumonia: An infectious second-hit model. <i>Journal of Critical Care</i> , 2020 , 59, 207-214	4	1
341	How may we improve clinical outcomes for patients hospitalized with acute exacerbations of chronic obstructive pulmonary disease? A narrative review about possible therapeutic and preventive strategies. <i>Expert Review of Respiratory Medicine</i> , 2020 , 14, 493-500	3.8	2
340	Reliability and Minimum Important Difference of Sputum Weight in Bronchiectasis. <i>Respiratory Care</i> , 2020 , 65, 1478-1487	2.1	0
339	Lymphopenic community acquired pneumonia as signature of severe COVID-19 infection. <i>Journal of Infection</i> , 2020 , 80, e23-e24	18.9	62
338	Ceftaroline for severe community-acquired pneumonia: A real-world two-centre experience in Italy and Spain. <i>International Journal of Antimicrobial Agents</i> , 2020 , 55, 105921	14.3	6

337	Assessment of a Loop-Mediated Isothermal Amplification (LAMP) Assay for the Rapid Detection of Pathogenic Bacteria from Respiratory Samples in Patients with Hospital-Acquired Pneumonia. <i>Microorganisms</i> , 2020 , 8,	4.9	12
336	Can Artificial Intelligence Improve the Management of Pneumonia. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	20
335	Cost-effectiveness Comparison of Ceftazidime/Avibactam Versus Meropenem in the Empirical Treatment of Hospital-acquired Pneumonia, Including Ventilator-associated Pneumonia, in Italy. <i>Clinical Therapeutics</i> , 2020 , 42, 802-817	3.5	2
334	Advances in molecular diagnostic tests for pneumonia. <i>Current Opinion in Pulmonary Medicine</i> , 2020 , 26, 241-248	3	6
333	Influenza management with new therapies. <i>Current Opinion in Pulmonary Medicine</i> , 2020 , 26, 215-221	3	3
332	Association between physical activity and risk of hospitalisation in bronchiectasis. <i>European Respiratory Journal</i> , 2020 , 55,	13.6	6
331	Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection. <i>Journal of Infectious Diseases</i> , 2020 , 221, 356-366	7	10
330	Gender differences in community-acquired pneumonia. <i>Minerva Medica</i> , 2020 , 111, 153-165	2.2	10
329	Defining Community-Acquired Pneumonia as a Public Health Threat: Arguments in Favor from Spanish Investigators. <i>Medical Sciences (Basel, Switzerland)</i> , 2020 , 8,	3.3	3
328	A pooled analysis of patients with wound infections in the Phase 3 REVIVE trials: randomized, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin structure infections. <i>Journal of Medical Microbiology</i> , 2020 , 69, 625-630	3.2	1
327	Early and Late Cardiovascular Events in Patients Hospitalized for Community-Acquired Pneumonia. <i>Archivos De Bronconeumologia</i> , 2020 , 56, 551-558	0.7	5
326	635. Efficacy, Pharmacokinetics (PK), and Safety Profile of MEDI3902, an Anti-Pseudomonas aeruginosa Bispecific Human Monoclonal Antibody in Mechanically Ventilated Intensive Care Unit Patients; Results of the Phase 2 EVADE Study Conducted by the Public-Private COVID-19 MAGNET Consortium in the Innovative Medicines Initiative (IMI) Program. <i>Chest</i> , 2020 , 157, 103-111	1	5
325	Economic analysis of ceftaroline fosamil for treating community-acquired pneumonia in Spain. <i>Journal of Medical Economics</i> , 2020 , 23, 148-155	2.4	
324	A multicentre analysis of Nocardia pneumonia in Spain: 2010-2016. <i>International Journal of Infectious Diseases</i> , 2020 , 90, 161-166	10.5	17
323	Programmed Disarming of the neutrophil proteome reduces the magnitude of inflammation. <i>Nature Immunology</i> , 2020 , 21, 135-144	19.1	89
322	Severe flu management: a point of view. <i>Intensive Care Medicine</i> , 2020 , 46, 153-162	14.5	15
321	Reply to Musher. <i>Journal of Infectious Diseases</i> , 2020 , 222, 334-335	7	1
320	Chest physiotherapy: An important adjuvant in critically ill mechanically ventilated patients with COVID-19. <i>Respiratory Physiology and Neurobiology</i> , 2020 , 282, 103529	2.8	21

319	Aetiological diagnosis in new adult outpatients with bronchiectasis:role of predictors derived from real life experience. <i>Respiratory Medicine</i> , 2020 , 172, 106090	4.6	1
318	Diagnostic accuracy of Gram staining when predicting staphylococcal hospital-acquired pneumonia and ventilator-associated pneumonia: a systematic review and meta-analysis. <i>Clinical Microbiology and Infection</i> , 2020 , 26, 1456-1463	9.5	2
317	International Survey to Establish Prioritized Outcomes for Trials in People With Coronavirus Disease 2019. <i>Critical Care Medicine</i> , 2020 , 48, 1612-1621	1.4	7
316	Coronavirus Disease-19: An Interim Evidence Synthesis of the World Association for Infectious Diseases and Immunological Disorders (Waidid). <i>Frontiers in Medicine</i> , 2020 , 7, 572485	4.9	10
315	Noninvasive Ventilation and High-Flow Nasal Therapy Administration in Chronic Obstructive Pulmonary Disease Exacerbations. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020 , 41, 786-797	3.9	0
314	Pneumonic versus Nonpneumonic Exacerbations of Chronic Obstructive Pulmonary Disease. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020 , 41, 817-829	3.9	3
313	Neumonía adquirida en la comunidad. Normativa de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR). Actualización 2020. <i>Archivos De Bronconeumología</i> , 2020 , 56, 1-10	0.7	11
312	The importance of airway and lung microbiome in the critically ill. <i>Critical Care</i> , 2020 , 24, 537	10.8	10
311	Is ventilated hospital-acquired pneumonia a worse entity than ventilator-associated pneumonia?. <i>European Respiratory Review</i> , 2020 , 29,	9.8	8
310	Reconsidering ventilator-associated pneumonia from a new dimension of the lung microbiome. <i>EBioMedicine</i> , 2020 , 60, 102995	8.8	9
309	COPD in the Intensive Care Unit. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020 , 41, 785	3.9	
308	International Perspective on the New 2019 American Thoracic Society/Infectious Diseases Society of America Community-Acquired Pneumonia Guideline: A Critical Appraisal by a Global Expert Panel. <i>Chest</i> , 2020 , 158, 1912-1918	5.3	6
307	Systemic Inflammatory Response and Outcomes in Community-Acquired Pneumonia Patients Categorized According to the Smoking Habit or Presence of Chronic Obstructive Pulmonary Disease. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	2
306	Lateral position during severe mono-lateral pneumonia: an experimental study. <i>Scientific Reports</i> , 2020 , 10, 19372	4.9	3
305	Feasibility of computerized adventitious respiratory sounds to assess the effects of airway clearance techniques in patients with bronchiectasis. <i>Physiotherapy Theory and Practice</i> , 2020 , 36, 1245-1255	1.5	2
304	Systematic review and meta-analysis of the safety of erythromycin compared to clarithromycin in adults and adolescents with pneumonia. <i>Journal of Chemotherapy</i> , 2020 , 32, 1-6	2.3	4
303	Community-Acquired Pneumonia Patients at Risk for Early and Long-term Cardiovascular Events Are Identified by Cardiac Biomarkers. <i>Chest</i> , 2019 , 156, 1080-1091	5.3	21
302	Effect of Corticosteroids on C-Reactive Protein in Patients with Severe Community-Acquired Pneumonia and High Inflammatory Response: The Effect of Lymphopenia. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	3

301	pneumonia in the twenty-first century: HIV-infected versus HIV-uninfected patients. <i>Expert Review of Anti-Infective Therapy</i> , 2019 , 17, 787-801	5.5	22
300	Serum levels of hyaluronic acid are associated with COPD severity and predict survival. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	16
299	Challenges in severe community-acquired pneumonia: a point-of-view review. <i>Intensive Care Medicine</i> , 2019 , 45, 159-171	14.5	49
298	Lymphocytopenia as a Predictor of Mortality in Patients with ICU-Acquired Pneumonia. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	17
297	Mucoid <i>Pseudomonas aeruginosa</i> alters sputum viscoelasticity in patients with non-cystic fibrosis bronchiectasis. <i>Respiratory Medicine</i> , 2019 , 154, 40-46	4.6	4
296	Letter from Spain. <i>Respirology</i> , 2019 , 24, 817-818	3.6	
295	Emerging strategies for the noninvasive diagnosis of nosocomial pneumonia. <i>Expert Review of Anti-Infective Therapy</i> , 2019 , 17, 523-533	5.5	7
294	Perspectives on synthetic pharmacotherapy for the treatment of nosocomial pneumonia. <i>Expert Opinion on Pharmacotherapy</i> , 2019 , 20, 1439-1448	4	1
293	Pure Viral Sepsis Secondary to Community-Acquired Pneumonia in Adults: Risk and Prognostic Factors. <i>Journal of Infectious Diseases</i> , 2019 , 220, 1166-1171	7	13
292	Short-Term Appraisal of the Effects and Safety of Manual Versus Ventilator Hyperinflation in an Animal Model of Severe Pneumonia. <i>Respiratory Care</i> , 2019 , 64, 760-770	2.1	7
291	Randomized Trial of Ceftazidime-Avibactam vs Meropenem for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (REPROVE): Analyses per US FDA-Specified End Points. <i>Open Forum Infectious Diseases</i> , 2019 , 6, ofz149	1	20
290	Multidrug Resistant Gram-Negative Bacteria in Community-Acquired Pneumonia. <i>Critical Care</i> , 2019 , 23, 79	10.8	44
289	Evaluation of the Magicplex Sepsis Real-Time Test for the Rapid Diagnosis of Bloodstream Infections in Adults. <i>Frontiers in Cellular and Infection Microbiology</i> , 2019 , 9, 56	5.9	13
288	Lymphopenic community-acquired pneumonia is associated with a dysregulated immune response and increased severity and mortality. <i>Journal of Infection</i> , 2019 , 78, 423-431	18.9	28
287	Elaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment Efficacy in Future Hospital-acquired/Ventilator-associated Bacterial Pneumonia Clinical Trials. <i>Clinical Infectious Diseases</i> , 2019 , 69, 1912-1918	11.6	9
286	PES Pathogens in Severe Community-Acquired Pneumonia. <i>Microorganisms</i> , 2019 , 7,	4.9	11
285	24th International Symposium on Infections in the Critically Ill Patient. <i>Medical Sciences (Basel, Switzerland)</i> , 2019 , 7,	3.3	1
284	Declining Mortality in Patients With Acute Respiratory Distress Syndrome: An Analysis of the Acute Respiratory Distress Syndrome Network Trials. <i>Critical Care Medicine</i> , 2019 , 47, 315-323	1.4	25

283	Optimal approaches to preventing severe community-acquired pneumonia. <i>Expert Review of Respiratory Medicine</i> , 2019 , 13, 1005-1018	3.8	2
282	Response. <i>Chest</i> , 2019 , 156, 415	5.3	
281	Bronchiectasis in India: results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry. <i>The Lancet Global Health</i> , 2019 , 7, e1269-e1279	13.6	57
280	Ventilator-Associated Pneumonia and PaO ₂ /FO Diagnostic Accuracy: Changing the Paradigm?. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	6
279	Addendum: Cillibiz, C.; Dominedic.; Nicolini, A.; Torres, A. PES Pathogens in Severe Community-Acquired Pneumonia. <i>Microorganisms</i> 2019, 7, 49. <i>Microorganisms</i> , 2019 , 7, 168	4.9	1
278	Comparative efficacy of linezolid and vancomycin for endotracheal tube MRSA biofilms from ICU patients. <i>Critical Care</i> , 2019 , 23, 251	10.8	9
277	Risk and Prognostic Factors in Very Old Patients with Sepsis Secondary to Community-Acquired Pneumonia. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	14
276	The association of cardiovascular failure with treatment for ventilator-associated lower respiratory tract infection. <i>Intensive Care Medicine</i> , 2019 , 45, 1753-1762	14.5	11
275	Current gaps in sepsis immunology: new opportunities for translational research. <i>Lancet Infectious Diseases</i> , 2019 , 19, e422-e436	25.5	88
274	Emerging antibiotics for community-acquired pneumonia. <i>Expert Opinion on Emerging Drugs</i> , 2019 , 24, 221-231	3.7	11
273	Early noninvasive ventilation treatment for respiratory failure due to severe community-acquired pneumonia. <i>Minerva Pneumologica</i> , 2019 , 58,	0.8	1
272	Non-invasive ventilation in palliative care: a systematic review. <i>Minerva Medica</i> , 2019 , 110, 555-563	2.2	2
271	Invasive and non-invasive diagnostic approaches for microbiological diagnosis of hospital-acquired pneumonia. <i>Critical Care</i> , 2019 , 23, 51	10.8	13
270	Clinical Factors Associated with a Shorter or Longer Course of Antibiotic Treatment in Patients with Exacerbations of Bronchiectasis: A Prospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	1
269	An overview of guidelines for the management of hospital-acquired and ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria. <i>Current Opinion in Infectious Diseases</i> , 2019 , 32, 656-662	5.4	18
268	Surveillance of iclaprim activity: in vitro susceptibility of Gram-positive skin infection pathogens collected from 2015 to 2016 from North America and Europe. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019 , 93, 154-158	2.9	8
267	Effect of Combined β -Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients With Community-Acquired Pneumonia. <i>Chest</i> , 2019 , 155, 795-804	5.3	18
266	The burden of community-acquired bacterial pneumonia in the era of antibiotic resistance. <i>Expert Review of Respiratory Medicine</i> , 2019 , 13, 139-152	3.8	53

265	An international perspective on hospitalized patients with viral community-acquired pneumonia. <i>European Journal of Internal Medicine</i> , 2019 , 60, 54-70	3.9	14
264	Developing definitions for invasive fungal diseases in critically ill adult patients in intensive care units. Protocol of the FUNgal infections Definitions in ICU patients (FUNDICU) project. <i>Mycoses</i> , 2019 , 62, 310-319	5.2	36
263	Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia. <i>Journal of Infectious Diseases</i> , 2019 , 219, 1536-1544	7	26
262	Reply to Head and Keynan. <i>Clinical Infectious Diseases</i> , 2019 , 68, 1433-1434	11.6	
261	Is One Sample Enough? β -Lactam Target Attainment and Penetration into Epithelial Lining Fluid Based on Multiple Bronchoalveolar Lavage Sampling Time Points in a Swine Pneumonia Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	4
260	Initial Inflammatory Profile in Community-acquired Pneumonia Depends on Time since Onset of Symptoms. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018 , 198, 370-378	10.2	23
259	Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study). <i>Intensive Care Medicine</i> , 2018 , 44, 438-448	14.5	62
258	Community-Acquired Legionella Pneumonia in Human Immunodeficiency Virus-Infected Adult Patients: A Matched Case-Control Study. <i>Clinical Infectious Diseases</i> , 2018 , 67, 958-961	11.6	6
257	Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review. <i>Respiratory Medicine</i> , 2018 , 137, 6-13	4.6	47
256	Detection of human cytomegalovirus in bronchoalveolar lavage of intensive care unit patients. <i>European Respiratory Journal</i> , 2018 , 51,	13.6	6
255	Surveillance of iclaprim activity: In vitro susceptibility of gram-positive pathogens collected from 2012 to 2014 from the United States, Asia Pacific, Latin American and Europe. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018 , 90, 329-334	2.9	14
254	The BRICS (Bronchiectasis Radiologically Indexed CT Score): A Multicenter Study Score for Use in Idiopathic and Postinfective Bronchiectasis. <i>Chest</i> , 2018 , 153, 1177-1186	5.3	24
253	A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1. <i>Clinical Infectious Diseases</i> , 2018 , 66, 1222-1229	11.6	30
252	IFN β /4 locus polymorphisms and IFN β circulating levels are associated with COPD severity and outcomes. <i>BMC Pulmonary Medicine</i> , 2018 , 18, 51	3.5	11
251	Corticosteroids in Patients Hospitalized With Community-Acquired Pneumonia: Systematic Review and Individual Patient Data Metaanalysis. <i>Clinical Infectious Diseases</i> , 2018 , 66, 346-354	11.6	59
250	A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study). <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	21
249	COPD 2017: A Year in Review. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2018 , 15, 118-122		
248	Acute respiratory distress syndrome in mechanically ventilated patients with community-acquired pneumonia. <i>European Respiratory Journal</i> , 2018 , 51,	13.6	26

247	Adjuvant therapies in critical care: steroids in community-acquired pneumonia. <i>Intensive Care Medicine</i> , 2018 , 44, 478-481	14.5	7
246	Treatment with long acting muscarinic antagonists stimulates serum levels of irisin in patients with COPD. <i>Pulmonary Pharmacology and Therapeutics</i> , 2018 , 48, 111-116	3.5	1
245	The effect of pulmonary surfactant on the in vitro activity of Iclaprim against common respiratory bacterial pathogens. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018 , 90, 64-66	2.9	1
244	Collagen Degradation and Formation Are Elevated in Exacerbated COPD Compared With Stable Disease. <i>Chest</i> , 2018 , 154, 798-807	5.3	19
243	Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study. <i>Intensive Care Medicine</i> , 2018 , 44, 1470-1482	14.5	76
242	Antivirals for influenza-Like Illness? A randomised Controlled trial of Clinical and Cost effectiveness in primary Care (ALIC E): the ALIC E protocol. <i>BMJ Open</i> , 2018 , 8, e021032	3	9
241	Burden and risk factors for community-acquired pneumonia: a multinational point prevalence study of hospitalised patients. <i>European Respiratory Journal</i> , 2018 , 52,	13.6	56
240	Community-acquired bacterial pneumonia in adult HIV-infected patients. <i>Expert Review of Anti-Infective Therapy</i> , 2018 , 16, 579-588	5.5	8
239	Characteristics and Management of Community-Acquired Pneumonia in the Era of Global Aging. <i>Medical Sciences (Basel, Switzerland)</i> , 2018 , 6,	3.3	14
238	The efficacy of inhaled antibiotics in non-cystic fibrosis bronchiectasis. <i>Expert Review of Respiratory Medicine</i> , 2018 , 12, 683-691	3.8	4
237	Twenty-year trend in mortality among hospitalized patients with pneumococcal community-acquired pneumonia. <i>PLoS ONE</i> , 2018 , 13, e0200504	3.7	18
236	Microorganisms resistant to conventional antimicrobials in acute exacerbations of chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2018 , 19, 119	7.3	14
235	Pneumonic and non-pneumonic exacerbations in bronchiectasis: Clinical and microbiological differences. <i>Journal of Infection</i> , 2018 , 77, 99-106	18.9	10
234	Community-acquired Pneumonia and Acute Respiratory Distress Syndrome: Prevalence, Risk, and Prognosis. <i>Clinical Pulmonary Medicine</i> , 2018 , 25, 100-106	0.3	1
233	Clinical Approach to Community-acquired Pneumonia. <i>Journal of Thoracic Imaging</i> , 2018 , 33, 273-281	5.6	6
232	Looking for Predictors of Early Readmission in Chronic Obstructive Pulmonary Disease: Every Effort Is Required. <i>Annals of the American Thoracic Society</i> , 2018 , 15, 1366	4.7	2
231	Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia. <i>Respiratory Medicine</i> , 2018 , 140, 115-121	4.6	6
230	Impact of Hypertonic Saline Solutions on Sputum Expectoration and Their Safety Profile in Patients with Bronchiectasis: A Randomized Crossover Trial. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2018 , 31, 281-289	3.8	20

229	Impact of bronchiectasis on outcomes of hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease: A propensity matched analysis. <i>Scientific Reports</i> , 2018 , 8, 9236	4.9	12
228	Severe community-acquired pneumonia: Characteristics and prognostic factors in ventilated and non-ventilated patients. <i>PLoS ONE</i> , 2018 , 13, e0191721	3.7	41
227	Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. <i>Lancet Infectious Diseases</i> , 2018 , 18, 285-295	25.5	207
226	Appraisal of systemic inflammation and diagnostic markers in a porcine model of VAP: secondary analysis from a study on novel preventive strategies. <i>Intensive Care Medicine Experimental</i> , 2018 , 6, 42	3.7	3
225	Adjunctive Therapies for Community-Acquired Pneumonia. <i>Clinics in Chest Medicine</i> , 2018 , 39, 753-764	5.3	7
224	Inhaled amikacin for severe Gram-negative pulmonary infections in the intensive care unit: current status and future prospects. <i>Critical Care</i> , 2018 , 22, 343	10.8	12
223	Community-acquired pneumonia as an emergency condition. <i>Current Opinion in Critical Care</i> , 2018 , 24, 531-539	3.5	22
222	Clinical variables predicting the risk of a hospital stay for longer than 7 days in patients with severe acute exacerbations of chronic obstructive pulmonary disease: a prospective study. <i>Respiratory Research</i> , 2018 , 19, 261	7.3	19
221	Management of severe acute exacerbations of COPD: an updated narrative review. <i>Multidisciplinary Respiratory Medicine</i> , 2018 , 13, 36	3	33
220	Treating HIV-Positive/Non-AIDS Patients for Community-Acquired Pneumonia with ART. <i>Current Infectious Disease Reports</i> , 2018 , 20, 46	3.9	1
219	Drugs that increase the risk of community-acquired pneumonia: a narrative review. <i>Expert Opinion on Drug Safety</i> , 2018 , 17, 991-1003	4.1	7
218	New guidelines for hospital-acquired pneumonia/ventilator-associated pneumonia: USA vs. Europe. <i>Current Opinion in Critical Care</i> , 2018 , 24, 347-352	3.5	43
217	Epidemiology of ICU-acquired pneumonia. <i>Current Opinion in Critical Care</i> , 2018 , 24, 325-331	3.5	33
216	Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections. <i>International Journal of Antimicrobial Agents</i> , 2018 , 52, 233-240	14.3	12
215	Summary of the international clinical guidelines for the management of hospital-acquired and ventilator-acquired pneumonia. <i>ERJ Open Research</i> , 2018 , 4,	3.5	23
214	Invasive Disease vs Urinary Antigen-Confirmed Pneumococcal Community-Acquired Pneumonia. <i>Chest</i> , 2017 , 151, 1311-1319	5.3	12
213	Seasonality of pathogens causing community-acquired pneumonia. <i>Respirology</i> , 2017 , 22, 778-785	3.6	29
212	Antibiotic therapy prior to hospital admission is associated with reduced septic shock and need for mechanical ventilation in patients with community-acquired pneumonia. <i>Journal of Infection</i> , 2017 , 74, 442-449	18.9	8

211	The research agenda in VAP/HAP: next steps. <i>Intensive Care Medicine</i> , 2017 , 43, 1389-1391	14.5	5
210	Research in community-acquired pneumonia: the next steps. <i>Intensive Care Medicine</i> , 2017 , 43, 1395-1397	4.5	5
209	Biomarkers kinetics in the assessment of ventilator-associated pneumonia response to antibiotics - results from the BioVAP study. <i>Journal of Critical Care</i> , 2017 , 41, 91-97	4	19
208	The Role of Neutrophil Elastase Inhibitors in Lung Diseases. <i>Chest</i> , 2017 , 152, 249-262	5.3	106
207	New Sepsis Definition (Sepsis-3) and Community-acquired Pneumonia Mortality. A Validation and Clinical Decision-Making Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 196, 1287-1297	10.2	103
206	Body Position and Ventilator-Associated Pneumonia Prevention. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017 , 38, 371-380	3.9	6
205	Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research. <i>European Respiratory Journal</i> , 2017 , 49,	13.6	149
204	Noninvasive Ventilation with Helium/Oxygen in Chronic Obstructive Pulmonary Disease Exacerbations. When Physiologic Improvement Does Not Translate into Clinical Benefit. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 195, 843-844	10.2	3
203	Community-Acquired Pneumococcal Pneumonia in Virologically Suppressed HIV-Infected Adult Patients: A Matched Case-Control Study. <i>Chest</i> , 2017 , 152, 295-303	5.3	12
202	Factors associated with hospitalization in bronchiectasis exacerbations: a one-year follow-up study. <i>Respiratory Research</i> , 2017 , 18, 176	7.3	19
201	Lymphopenic Community Acquired Pneumonia (L-CAP), an Immunological Phenotype Associated with Higher Risk of Mortality. <i>EBioMedicine</i> , 2017 , 24, 231-236	8.8	43
200	Randomized, multicenter trial of lateral Trendelenburg versus semirecumbent body position for the prevention of ventilator-associated pneumonia. <i>Intensive Care Medicine</i> , 2017 , 43, 1572-1584	14.5	20
199	Investigational drugs in phase I and phase II clinical trials for the treatment of community-acquired pneumonia. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 1239-1248	5.9	7
198	Risk factors for multidrug-resistant pathogens in bronchiectasis exacerbations. <i>BMC Infectious Diseases</i> , 2017 , 17, 659	4	17
197	The burden of PCV13 serotypes in hospitalized pneumococcal pneumonia in Spain using a novel urinary antigen detection test. CAPA study. <i>Vaccine</i> , 2017 , 35, 5264-5270	4.1	17
196	Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	2
195	International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society	13.6	425
194	European Respiratory Society guidelines for the management of adult bronchiectasis. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	451

193	Respiratory research networks in Europe and beyond: aims, achievements and aspirations for the 21st century. <i>Breathe</i> , 2017 , 13, 209-215	1.8	0
192	A Phase II Randomized, Double-blind, Multicenter Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin for the Treatment of Nosocomial Pneumonia Suspected or Confirmed to be Due to Gram-positive Pathogens. <i>Clinical Therapeutics</i> , 2017 , 39, 1706-1718	3.5	16
191	Intensive care unit patients with lower respiratory tract nosocomial infections: the ENIRRI project. <i>ERJ Open Research</i> , 2017 , 3,	3.5	15
190	Has Mortality of Community-Acquired Pneumonia Really Reduced?. <i>Clinical Pulmonary Medicine</i> , 2017 , 24, 258-262	0.3	1
189	Discontinuing noninvasive ventilation in severe chronic obstructive pulmonary disease exacerbations: a randomised controlled trial. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	13
188	Intensive care unit-acquired pneumonia due to <i>Pseudomonas aeruginosa</i> with and without multidrug resistance. <i>Journal of Infection</i> , 2017 , 74, 142-152	18.9	61
187	Community-acquired pneumonia in adults: Highlighting missed opportunities for vaccination. <i>European Journal of Internal Medicine</i> , 2017 , 37, 13-18	3.9	14
186	Systemic Biomarkers of Collagen and Elastin Turnover Are Associated With Clinically Relevant Outcomes in COPD. <i>Chest</i> , 2017 , 151, 47-59	5.3	43
185	Phenotypic shift in <i>Pseudomonas aeruginosa</i> populations from cystic fibrosis lungs after 2-week antipseudomonal treatment. <i>Journal of Cystic Fibrosis</i> , 2017 , 16, 222-229	4.1	26
184	Increased incidence of co-infection in critically ill patients with influenza. <i>Intensive Care Medicine</i> , 2017 , 43, 48-58	14.5	109
183	Immunological profiling to assess disease severity and prognosis in community-acquired pneumonia. <i>Lancet Respiratory Medicine</i> , 2017 , 5, e35-e36	35.1	14
182	Comparison of two prognostic scores (BSI and FACED) in a Spanish cohort of adult patients with bronchiectasis and improvement of the FACED predictive capacity for exacerbations. <i>PLoS ONE</i> , 2017 , 12, e0175171	3.7	24
181	Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial. <i>PLoS ONE</i> , 2017 , 12, e0178022	3.7	9
180	Time to blood culture positivity as a predictor of clinical outcomes and severity in adults with bacteremic pneumococcal pneumonia. <i>PLoS ONE</i> , 2017 , 12, e0182436	3.7	15
179	Predictors of treatment failure and clinical stability in patients with community acquired pneumonia. <i>Annals of Translational Medicine</i> , 2017 , 5, 443	3.2	17
178	What's new in severe community-acquired pneumonia? Corticosteroids as adjunctive treatment to antibiotics. <i>Intensive Care Medicine</i> , 2016 , 42, 1276-8	14.5	4
177	Predicting In-Hospital Treatment Failure (17 days) in Patients with COPD Exacerbation Using Antibiotics and Systemic Steroids. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2016 , 13, 82-92	2	17
176	Pneumonia in 2016: towards better care. <i>Lancet Respiratory Medicine</i> , 2016 , 4, 949-951	35.1	2

175	Readmission in COPD patients: should we consider it a marker of quality of care or a marker of a more severe disease with a worse prognosis?. <i>European Respiratory Journal</i> , 2016 , 48, 279-81	13.6	10
174	Serum levels of immunoglobulins and severity of community-acquired pneumonia. <i>BMJ Open Respiratory Research</i> , 2016 , 3, e000152	5.6	15
173	Community-acquired pneumonia related to intracellular pathogens. <i>Intensive Care Medicine</i> , 2016 , 42, 1374-86	14.5	48
172	Emerging drugs for nosocomial pneumonia. <i>Expert Opinion on Emerging Drugs</i> , 2016 , 21, 331-41	3.7	9
171	Polymicrobial community-acquired pneumonia: An emerging entity. <i>Respirology</i> , 2016 , 21, 65-75	3.6	23
170	Piperacillin population pharmacokinetics in critically ill patients with multiple organ dysfunction syndrome receiving continuous venovenous haemodiafiltration: effect of type of dialysis membrane on dosing requirements. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 1651-9	5.1	18
169	The clinical management of lower respiratory tract infections. <i>Expert Review of Respiratory Medicine</i> , 2016 , 10, 441-452	3.8	1
168	Community acquired pneumonia in asthma: Not a threatening combination. <i>Respiratory Medicine</i> , 2016 , 112, 136	4.6	
167	The EMBARC European Bronchiectasis Registry: protocol for an international observational study. <i>ERJ Open Research</i> , 2016 , 2,	3.5	84
166	Procalcitonin (PCT) levels for ruling-out bacterial coinfection in ICU patients with influenza: A CHAID decision-tree analysis. <i>Journal of Infection</i> , 2016 , 72, 143-51	18.9	70
165	Bacteraemia in outpatients with community-acquired pneumonia. <i>European Respiratory Journal</i> , 2016 , 47, 654-7	13.6	6
164	Readmission for Acute Exacerbation within 30 Days of Discharge Is Associated with a Subsequent Progressive Increase in Mortality Risk in COPD Patients: A Long-Term Observational Study. <i>PLoS ONE</i> , 2016 , 11, e0150737	3.7	53
163	Personalizing pneumococcal vaccination recommendations: The Saudi Thoracic Society guidelines. <i>Annals of Thoracic Medicine</i> , 2016 , 11, 89-90	2.2	
162	Microbial Etiology of Pneumonia: Epidemiology, Diagnosis and Resistance Patterns. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	100
161	Predictors of Severe Sepsis among Patients Hospitalized for Community-Acquired Pneumonia. <i>PLoS ONE</i> , 2016 , 11, e0145929	3.7	44
160	Pneumococcal vaccination. <i>Current Opinion in Infectious Diseases</i> , 2016 , 29, 187-96	5.4	22
159	Therapy with proton-pump inhibitors for gastroesophageal reflux disease does not reduce the risk for severe exacerbations in COPD. <i>Respirology</i> , 2016 , 21, 883-90	3.6	22
158	Impact of amoxicillin therapy on resistance selection in patients with community-acquired lower respiratory tract infections: a randomized, placebo-controlled study. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 3258-3267	5.1	21

157	The effects of direct hemoperfusion using a polymyxin B-immobilized column in a pig model of severe <i>Pseudomonas aeruginosa</i> pneumonia. <i>Annals of Intensive Care</i> , 2016 , 6, 58	8.9	3
156	Laboratory diagnosis of pneumonia in the molecular age. <i>European Respiratory Journal</i> , 2016 , 48, 1764-1778	13.8	69
155	Nonantibiotic Adjunctive Therapies for Community-Acquired Pneumonia (Corticosteroids and Beyond): Where Are We with Them?. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2016 , 37, 913-922	2.9	5
154	What is the clinical relevance of drug-resistant pneumococcus?. <i>Current Opinion in Pulmonary Medicine</i> , 2016 , 22, 227-34	3	29
153	Advances in antibiotic therapy in the critically ill. <i>Critical Care</i> , 2016 , 20, 133	10.8	70
152	Prognostic assessment in COPD without lung function: the B-AE-D indices. <i>European Respiratory Journal</i> , 2016 , 47, 1635-44	13.6	29
151	Community-Acquired Pneumonia Due to Multidrug- and Non-Multidrug-Resistant <i>Pseudomonas aeruginosa</i> . <i>Chest</i> , 2016 , 150, 415-25	5.3	66
150	Multilobar bilateral and unilateral chest radiograph involvement: implications for prognosis in hospitalised community-acquired pneumonia. <i>European Respiratory Journal</i> , 2016 , 48, 257-61	13.6	7
149	Predictive and prognostic factors in patients with blood-culture-positive community-acquired pneumococcal pneumonia. <i>European Respiratory Journal</i> , 2016 , 48, 797-807	13.6	24
148	The SAATELLITE and EVADE Clinical Studies Within the COMBACTE Consortium: A Public-Private Collaborative Effort in Designing and Performing Clinical Trials for Novel Antibacterial Drugs to Prevent Nosocomial Pneumonia. <i>Clinical Infectious Diseases</i> , 2016 , 63 Suppl 2, S46-51	11.6	16
147	Response. <i>Chest</i> , 2016 , 150, 757	5.3	
146	Prone position and VAP incidence in the PROSEVA trial: attention to the causal question when interpreting competing risk analysis. <i>Intensive Care Medicine</i> , 2016 , 42, 2119-2120	14.5	2
145	Clinical management of community acquired pneumonia in the elderly patient. <i>Expert Review of Respiratory Medicine</i> , 2016 , 10, 1211-1220	3.8	17
144	Endothelial adhesion molecules and multiple organ failure in patients with severe sepsis. <i>Cytokine</i> , 2016 , 88, 267-273	4	31
143	New aspects in the management of pneumonia. <i>Critical Care</i> , 2016 , 20, 267	10.8	16
142	Pneumonia presenting with organ dysfunctions: Causative microorganisms, host factors and outcome. <i>Journal of Infection</i> , 2016 , 73, 419-426	18.9	20
141	Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data meta-analysis. <i>Influenza and Other Respiratory Viruses</i> , 2016 , 10, 192-204	5.6	46
140	Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 677-86	27.4	306

139	Respiratory infections management: Still a challenge. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015 , 32, 117-8	3.5	1
138	Outcomes in patients with community-acquired pneumonia admitted to the intensive care unit. <i>Respiratory Medicine</i> , 2015 , 109, 743-50	4.6	20
137	Endotracheal tube biofilm translocation in the lateral Trendelenburg position. <i>Critical Care</i> , 2015 , 19, 59	10.8	16
136	Year in review in Intensive Care Medicine 2014: II. ARDS, airway management, ventilation, adjuvants in sepsis, hepatic failure, symptoms assessment and management, palliative care and support for families, prognostication, organ donation, outcome, organisation and research methodology. <i>Intensive Care Medicine</i> , 2015 , 44, 288-304	14.5	6
135	The Effect of Macrolide Resistance on the Presentation and Outcome of Patients Hospitalized for Streptococcus pneumoniae Pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 191, 1265-72	10.2	50
134	The clinical positioning of telavancin in Europe. <i>International Journal of Antimicrobial Agents</i> , 2015 , 45, 213-20	14.3	21
133	Upper respiratory symptoms worsen over time and relate to clinical phenotype in chronic obstructive pulmonary disease. <i>Annals of the American Thoracic Society</i> , 2015 , 12, 997-1004	4.7	10
132	Community-acquired pneumonia. <i>Lancet, The</i> , 2015 , 386, 1097-108	40	267
131	Clinical Management of Bacterial Pneumonia 2015 ,		7
130	Etiology of Non-Cystic Fibrosis Bronchiectasis in Adults and Its Correlation to Disease Severity. <i>Annals of the American Thoracic Society</i> , 2015 , 12, 1764-70	4.7	186
129	Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. <i>Thorax</i> , 2015 , 70, 984-9	7.3	153
128	Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 5520-8	5.9	46
127	Sensitivity, Specificity, and Positivity Predictors of the Pneumococcal Urinary Antigen Test in Community-Acquired Pneumonia. <i>Annals of the American Thoracic Society</i> , 2015 , 12, 1482-9	4.7	33
126	Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia. <i>Annals of the American Thoracic Society</i> , 2015 , 12, 153-60	4.7	84
125	New antimicrobial approaches to gram positive respiratory infections. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015 , 32, 137-43	3.5	12
124	Pseudomonas aeruginosa nosocomial pneumonia: impact of pneumonia classification. <i>Infection Control and Hospital Epidemiology</i> , 2015 , 36, 1190-7	2	29
123	Mannose-binding lectin protein and its association to clinical outcomes in COPD: a longitudinal study. <i>Respiratory Research</i> , 2015 , 16, 150	7.3	12
122	Importance of a registered and structured protocol when conducting systematic reviews: comments about nebulized antibiotics for ventilator-associated pneumonia. <i>Critical Care</i> , 2015 , 19, 298	10.8	1

121	Polymicrobial intensive care unit-acquired pneumonia: prevalence, microbiology and outcome. <i>Critical Care</i> , 2015 , 19, 450	10.8	30
120	Continuous control of tracheal cuff pressure for VAP prevention: a collaborative meta-analysis of individual participant data. <i>Annals of Intensive Care</i> , 2015 , 5, 43	8.9	27
119	Streptococcus pneumoniae-associated pneumonia complicated by purulent pericarditis: case series. <i>Jornal Brasileiro De Pneumologia</i> , 2015 , 41, 389-94	1.1	7
118	Ceftobiprole for the treatment of pneumonia: a European perspective. <i>Drug Design, Development and Therapy</i> , 2015 , 9, 4565-72	4.4	13
117	Concept for a study design in patients with severe community-acquired pneumonia: A randomised controlled trial with a novel IGM-enriched immunoglobulin preparation - The CIGMA study. <i>Respiratory Medicine</i> , 2015 , 109, 758-67	4.6	28
116	Impact of COPD in the outcome of ICU-acquired pneumonia with and without previous intubation. <i>Chest</i> , 2015 , 147, 1530-1538	5.3	8
115	Treatment for hospitalized patients with severe community-acquired pneumonia--reply. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 2184-5	27.4	
114	Microbiology and outcomes of community acquired pneumonia in non cystic-fibrosis bronchiectasis patients. <i>Journal of Infection</i> , 2015 , 71, 28-36	18.9	18
113	Endotracheal tubes for critically ill patients: an in vivo analysis of associated tracheal injury, mucociliary clearance, and sealing efficacy. <i>Chest</i> , 2015 , 147, 1327-1335	5.3	21
112	Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: risk and prognosis. <i>European Respiratory Journal</i> , 2015 , 45, 1353-63	13.6	33
111	Professions and Working Conditions Associated With Community-Acquired Pneumonia. <i>Archivos De Bronconeumologia</i> , 2015 , 51, 627-31	0.7	6
110	Year in review in Intensive Care Medicine 2014: I. Cardiac dysfunction and cardiac arrest, ultrasound, neurocritical care, ICU-acquired weakness, nutrition, acute kidney injury, and miscellaneous. <i>Intensive Care Medicine</i> , 2015 , 41, 179-191	14.5	5
109	Corticosteroids for severe CAP: the pros. <i>Revista Brasileira De Terapia Intensiva</i> , 2015 , 27, 202-4	1.2	2
108	Year in review in Intensive Care Medicine 2013: I. Acute kidney injury, ultrasound, hemodynamics, cardiac arrest, transfusion, neurocritical care, and nutrition. <i>Intensive Care Medicine</i> , 2014 , 40, 147-59	14.5	22
107	IgA level in plasma as a differential factor for influenza infection in severe viral pneumonia. <i>Journal of Clinical Virology</i> , 2014 , 59, 135-6	14.5	1
106	Severity and outcomes of community acquired pneumonia in asthmatic patients. <i>Respiratory Medicine</i> , 2014 , 108, 1713-22	4.6	10
105	Should ultrasound be included in the initial assessment of respiratory patients?. <i>Lancet Respiratory Medicine</i> , 2014 , 2, 599-600	35.1	4
104	Inhaled corticosteroids do not influence the early inflammatory response and clinical presentation of hospitalized subjects with COPD exacerbation. <i>Respiratory Care</i> , 2014 , 59, 1550-9	2.1	8

103	Epidemiology, antibiotic therapy and clinical outcomes of healthcare-associated pneumonia in critically ill patients: a Spanish cohort study. <i>Intensive Care Medicine</i> , 2014 , 40, 572-81	14.5	46
102	Community-acquired lung respiratory infections in HIV-infected patients: microbial aetiology and outcome. <i>European Respiratory Journal</i> , 2014 , 43, 1698-708	13.6	42
101	Impact of microbial ecology on accuracy of surveillance cultures to predict multidrug resistant microorganisms causing ventilator-associated pneumonia. <i>Journal of Infection</i> , 2014 , 69, 333-40	18.9	7
100	Exertional hypoxemia in stable COPD is common and predicted by circulating proadrenomedullin. <i>Chest</i> , 2014 , 146, 328-338	5.3	18
99	Importance of Legionella pneumophila in the etiology of severe community-acquired pneumonia in Santiago, Chile. <i>Chest</i> , 2014 , 145, 290-296	5.3	20
98	Decrease in mortality in severe community-acquired pneumococcal pneumonia: impact of improving antibiotic strategies (2000-2013). <i>Chest</i> , 2014 , 146, 22-31	5.3	56
97	Noninvasive ventilation in withdrawal from mechanical ventilation. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2014 , 35, 507-18	3.9	9
96	Ventilator-associated pneumonia. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2014 , 35, 469-81	3.9	41
95	Passive smoking at home is a risk factor for community-acquired pneumonia in older adults: a population-based case-control study. <i>BMJ Open</i> , 2014 , 4, e005133	3	17
94	Inhaled corticosteroids and systemic inflammatory response in community-acquired pneumonia: a prospective clinical study. <i>Respirology</i> , 2014 , 19, 929-35	3.6	14
93	Predicting treatment failure in patients with community acquired pneumonia: a case-control study. <i>Respiratory Research</i> , 2014 , 15, 75	7.3	16
92	Author's response to CAP and HCAP are different? An unresolved question <i>Thorax</i> , 2014 , 69, 677-8	7.3	
91	A worldwide perspective of nursing home-acquired pneumonia compared with community-acquired pneumonia. <i>Respiratory Care</i> , 2014 , 59, 1078-85	2.1	36
90	Importance of Aspergillus spp. isolation in Acute exacerbations of severe COPD: prevalence, factors and follow-up: the FUNGI-COPD study. <i>Respiratory Research</i> , 2014 , 15, 17	7.3	35
89	Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis. <i>Respiratory Research</i> , 2014 , 15, 27	7.3	30
88	Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. <i>Lancet Respiratory Medicine</i> , 2014 , 2, 395-404	35.1	405
87	Detection of pneumonia associated pathogens using a prototype multiplexed pneumonia test in hospitalized patients with severe pneumonia. <i>PLoS ONE</i> , 2014 , 9, e110566	3.7	25
86	Lung abscess due to Streptococcus pneumoniae: a case series and brief review of the literature. <i>Pneumonologia i Alergologia Polska</i> , 2014 , 82, 276-85		3

85	Nosocomial pneumonia in the intensive care unit: how should treatment failure be predicted?. <i>Revista Brasileira De Terapia Intensiva</i> , 2014 , 26, 208-11	1.2	5
84	Impact of chronic liver disease in intensive care unit acquired pneumonia: a prospective study. <i>Intensive Care Medicine</i> , 2013 , 39, 1776-84	14.5	17
83	Influence of previous use of inhaled corticoids on the development of pleural effusion in community-acquired pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013 , 187, 1241-8	10.2	40
82	IgM levels in plasma predict outcome in severe pandemic influenza. <i>Journal of Clinical Virology</i> , 2013 , 58, 564-7	14.5	23
81	Systemic corticosteroids for community-acquired pneumonia: reasons for use and lack of benefit on outcome. <i>Respirology</i> , 2013 , 18, 263-71	3.6	24
80	Thrombocytosis is a marker of poor outcome in community-acquired pneumonia. <i>Chest</i> , 2013 , 143, 767-775	3.5	32
79	Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective. <i>Thorax</i> , 2013 , 68, 997-9	7.3	96
78	Validation of predictors of adverse outcomes in hospital-acquired pneumonia in the ICU. <i>Critical Care Medicine</i> , 2013 , 41, 2151-61	1.4	42
77	Risk factors for community-acquired pneumonia in adults in Europe: a literature review. <i>Thorax</i> , 2013 , 68, 1057-65	7.3	341
76	Microbial aetiology of healthcare associated pneumonia in Spain: a prospective, multicentre, case-control study. <i>Thorax</i> , 2013 , 68, 1007-14	7.3	66
75	Pneumonic and nonpneumonic exacerbations of COPD: inflammatory response and clinical characteristics. <i>Chest</i> , 2013 , 144, 1134-1142	5.3	71
74	Systemic inflammatory pattern of patients with community-acquired pneumonia with and without COPD. <i>Chest</i> , 2013 , 143, 1009-1017	5.3	42
73	Impact of age and comorbidity on cause and outcome in community-acquired pneumonia. <i>Chest</i> , 2013 , 144, 999-1007	5.3	122
72	Response. <i>Chest</i> , 2013 , 144, 1976	5.3	2
71	A new molecular diagnostic tool for pneumocystis jirovecii-pneumonia (PjP) detection: Results from European multicenter clinical study CS-2011.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e20652-e20652	2.2	
70	Cytokine activation patterns and biomarkers are influenced by microorganisms in community-acquired pneumonia. <i>Chest</i> , 2012 , 141, 1537-1545	5.3	75
69	DEVELOPMENT AND VALIDATION OF A HIGH PERFORMANCE LIQUID CHROMATOGRAPHY METHOD TO DETERMINE VANCOMYCIN CONCENTRATIONS IN PLASMA AND PIG PULMONARY TISSUE. <i>Journal of Liquid Chromatography and Related Technologies</i> , 2012 , 35, 240-257	1.3	1
68	Community-acquired pneumonia in outpatients: aetiology and outcomes. <i>European Respiratory Journal</i> , 2012 , 40, 931-8	13.6	51

67	Bacterial co-infection with H1N1 infection in patients admitted with community acquired pneumonia. <i>Journal of Infection</i> , 2012 , 65, 223-30	18.9	59
66	Biomarkers and community-acquired pneumonia: tailoring management with biological data. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2012 , 33, 266-71	3.9	28
65	Influenza A (H1N1) Pneumonia. <i>Clinical Pulmonary Medicine</i> , 2012 , 19, 246-253	0.3	1
64	Invasive Pneumococcal Disease Today. <i>Clinical Pulmonary Medicine</i> , 2012 , 19, 191-198	0.3	2
63	Association between systemic corticosteroids and outcomes of intensive care unit-acquired pneumonia. <i>Critical Care Medicine</i> , 2012 , 40, 2552-61	1.4	29
62	Pandemic and post-pandemic influenza A (H1N1) infection in critically ill patients. <i>Critical Care</i> , 2011 , 15, R286	10.8	49
61	CD4+ cell counts and HIV-RNA levels do not predict outcomes of community-acquired pneumonia in hospitalized HIV-infected patients. <i>International Journal of Infectious Diseases</i> , 2011 , 15, e822-7	10.5	9
60	The strange case of community-acquired pneumonia in COPD. <i>Chest</i> , 2011 , 139, 483-485	5.3	7
59	Community-acquired polymicrobial pneumonia in the intensive care unit: aetiology and prognosis. <i>Critical Care</i> , 2011 , 15, R209	10.8	78
58	Microbial aetiology of community-acquired pneumonia and its relation to severity. <i>Thorax</i> , 2011 , 66, 340-63	7.3	185
57	Treatment guidelines and outcomes of hospital-acquired and ventilator-associated pneumonia. <i>Clinical Infectious Diseases</i> , 2010 , 51 Suppl 1, S48-53	11.6	75
56	Nosocomial pneumonia in the intensive care unit acquired by mechanically ventilated versus nonventilated patients. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010 , 182, 1533-9	10.2	125
55	Update in community-acquired and nosocomial pneumonia 2009. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010 , 181, 782-7	10.2	21
54	Rethinking the concepts of community-acquired and health-care-associated pneumonia. <i>Lancet Infectious Diseases</i> , 2010 , 10, 279-87	25.5	154
53	Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results. <i>Archives of Internal Medicine</i> , 2009 , 169, 1515-24		78
52	A prediction rule for estimating the risk of bacteremia in patients with community-acquired pneumonia. <i>Clinical Infectious Diseases</i> , 2009 , 49, 409-16	11.6	70
51	Severe community-acquired pneumonia: validation of the Infectious Diseases Society of America/American Thoracic Society guidelines to predict an intensive care unit admission. <i>Clinical Infectious Diseases</i> , 2009 , 48, 377-85	11.6	116
50	Reply to Charles et al.. <i>Clinical Infectious Diseases</i> , 2009 , 48, 1796-1797	11.6	2

49	Defining, treating and preventing hospital acquired pneumonia: European perspective. <i>Intensive Care Medicine</i> , 2009 , 35, 9-29	14.5	318
48	Reply to van Saene et al.. <i>Intensive Care Medicine</i> , 2009 , 35, 1817-1817	14.5	1
47	Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial. <i>Clinical Infectious Diseases</i> , 2008 , 46, 1499-509	11.6	62
46	Pneumonia severity index class v patients with community-acquired pneumonia: characteristics, outcomes, and value of severity scores. <i>Chest</i> , 2007 , 132, 515-22	5.3	85
45	Impact of alcohol abuse in the etiology and severity of community-acquired pneumonia. <i>Chest</i> , 2006 , 129, 1219-25	5.3	118
44	Fungal pneumonia, chronic respiratory diseases and glucocorticoids. <i>Medical Mycology</i> , 2006 , 44, S207-S211	3.1	6
43	Influencia de las resistencias bacterianas sobre la eficiencia del tratamiento antibiótico de las agudizaciones de la bronquitis crónica en España. <i>Pharmacoeconomics - Spanish Research Articles</i> , 2006 , 3, 109-122		
42	The Role of Viruses in the Aetiology of Community-Acquired Pneumonia in Adults. <i>Antiviral Therapy</i> , 2006 , 11, 351-359	1.6	75
41	Diagnosing ventilator-associated pneumonia. <i>New England Journal of Medicine</i> , 2004 , 350, 433-5	59.2	68
40	Causes and predictors of nonresponse to treatment of intensive care unit-acquired pneumonia. <i>Critical Care Medicine</i> , 2004 , 32, 938-45	1.4	108
39	Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. <i>Clinical Infectious Diseases</i> , 2003 , 36, 389-95	11.6	295
38	Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis. <i>Archives of Internal Medicine</i> , 2002 , 162, 1849-58		237
37	Effects of bronchoalveolar lavage volume on arterial oxygenation in mechanically ventilated patients with pneumonia. <i>Intensive Care Medicine</i> , 2001 , 27, 384-93	14.5	30
36	Diagnosis of pneumonia and monitoring of infection eradication. <i>Drugs</i> , 2000 , 60, 1289-302	12.1	12
35	Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1999 , 159, 1835-42	10.2	147
34	Bacterial colonization patterns in mechanically ventilated patients with traumatic and medical head injury. Incidence, risk factors, and association with ventilator-associated pneumonia. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1999 , 159, 188-98	10.2	265
33	Clinical diagnosis of ventilator associated pneumonia revisited: comparative validation using immediate post-mortem lung biopsies. <i>Thorax</i> , 1999 , 54, 867-73	7.3	317
32	Supine body position as a risk factor for nosocomial pneumonia in mechanically ventilated patients: a randomised trial. <i>Lancet, The</i> , 1999 , 354, 1851-8	40	1014

- 31 Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. *American Journal of Respiratory and Critical Care Medicine*, **1998**, 157, 1498-505 10.2 351
- 30 Prognostic factors of severe Legionella pneumonia requiring admission to ICU. *American Journal of Respiratory and Critical Care Medicine*, **1997**, 156, 1467-72 10.2 87
- 29 Significance of the isolation of Candida species from respiratory samples in critically ill, non-neutropenic patients. An immediate postmortem histologic study. *American Journal of Respiratory and Critical Care Medicine*, **1997**, 156, 583-90 10.2 676
- 28 Mechanisms of abnormal gas exchange in patients with pneumonia. *Anesthesiology*, **1991**, 75, 782-9 4.3 45
- 27 Severe community-acquired pneumonia. Epidemiology and prognostic factors. *The American Review of Respiratory Disease*, **1991**, 144, 312-8 469
- 26 Incidence, risk, and prognosis factors of nosocomial pneumonia in mechanically ventilated patients. *The American Review of Respiratory Disease*, **1990**, 142, 523-8 749
- 25 Epidemiology of Community-Acquired Pneumonia Outside Hospital1-4
- 24 Empirical Treatment of Community-Acquired Pneumonia: Current Guidelines63-100
- 23 General Pharmacological Considerations in Antibiotic Treatment of Community-Acquired Pneumonia127-152
- 22 β -Lactams in the Therapy of Community-Acquired Pneumonia153-169
- 21 Macrolides and Ketolides171-191
- 20 Non-Responding Pneumonia213-227
- 19 Role of Fluoroquinolones in the Treatment of Community-Acquired Pneumonia193-212
- 18 Epidemiology of Adult Hospitalized Community-Acquired Pneumonia5-19
- 17 Pathogen Directed Antimicrobial Treatment of Pneumonia101-126
- 16 Adjunctive Therapy in Community-Acquired Pneumonia245-262
- 15 Microbiological Diagnosis of Community-Acquired Pneumonia43-61
- 14 Microbial Aetiology and Antibiotic Resistances in Community-Acquired Pneumonia21-41

13	Influenza and Pneumococcal Vaccination for Prevention of Community-Acquired Pneumonia in Immunocompetent Adults229-244	
12	Pathophysiology of Pneumonia63-78	1
11	Magioplex™ Sepsis real-time test for the rapid diagnosis of bloodstream infections in adults	1
10	Microbiological Diagnosis of Respiratory Infections in the Immunocompromised29-52	1
9	Diagnosis of Pneumonia in Immunocompromised Patient53-93	1
8	Chronic Non-Infectious Pulmonary Complications in Haematopoietic Stem Cell Transplantation257-281	1
7	Pulmonary Infections in Patients on Chronic Glucocorticoid Treatment283-304	
6	Intensive Care Management in the Immunocompromised Patient with Pulmonary Infiltrates305-323	
5	Current Strategies in the Treatment of Fungal Infections in the Intensive Care Unit Setting349-381	
4	Current Strategies and Future Directions in Cytomegalovirus (CMV) Pneumonitis383-400	
3	Pulmonary Infections in HIV Patients in the Highly Active Antiretroviral Therapy Era117-141	
2	Neutropenia143-196	
1	Identification of circulating microRNA profiles associated with pulmonary function and radiologic features in survivors of SARS-CoV-2-induced ARDS. <i>Emerging Microbes and Infections</i> ,1-67	18,9 0